Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies

Metabolic Syndrome and Related Disorders

Volumn 12, Issue 2, 2014, Pages 125-131

  Literáti Nagy, Botond ^a   Tory, Kálmán ^b   Peitl, Barna ^c   Bajza, Ágnes ^b   Korányi, László ^a   Literáti Nagy, Zsuzsanna ^d   Hooper, Philip L ^e   Vígh, László ^f   Szilvássy, Zoltán ^c  

^a Drug Research Center Ltd   (Hungary)

^b N Gene Research and Development Ltd   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; OXIMES; PIPERIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; VASODILATION;

EID: 84894418103     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2013.0098     Document Type: Article

References (41)

1. DeFronzo RA. The triumvirate: B-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-687
2. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocr Rev 2001;22: 36-52
3. Baron AD. Insulin resistance and vascular function. J Diabetes Complications 2002;16:92-102
4. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 2003;3:279-288
5. Feener EP, King GL. Endothelial dysfunction in diabetes mellitus: Role in cardiovascular disease. Heart Fail Monit 2001;1:74-82
6. Althouse AD, Abbott JD, Sutton-Tyrrell K, et al. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: Results from the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Diabetes Care 2013;36:3269-3275
7. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003;8(Suppl 8A):111S-115S.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471
9. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377: 454-457
10. Nagy L, Kao HY, Love JD, et al. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev 1999;13:3209-3216
11. Chung J, Nguyen AK, Henstridge DC, et al. HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA 2008;105:1739-1744
12. Crul T, Toth N, Piotto S, et al. Hydroximic acid derivatives: Pleiotrophic HSP co-inducers restoring homeostasis and robustness. Curr Pharm Des 2013;19:309-346
13. Halmosi R, Berente Z, Osz E, et al. Effect of poly(ADPribose) polymerase inhibitors on the ischemia-reperfusioninduced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol Pharmacol 2001;59:1497-1505
14. Szabados E, Literati-Nagy P, Farkas B, et al. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem Pharmacol 2000;59:937-945
15. Zhang D, Ke L, Mackovicova K, et al. Effects of different small HSPB members on contractile dysfunction and structural changes in a Drosophila melanogaster model for atrial fibrillation. J Mol Cell Cardiol 2011;51:381-389
16. Porszasz R, Legvari G, Pataki T, et al. Hepatic insulin sensitizing substance: A novel sensocrine mechanism to increase insulin sensitivity in anaesthetized rats. Br J Pharmacol 2003;139:1171-1179
17. Cittadini A, Napoli R, Monti MG, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012;61:944-953
18. S Wallenstein, CL Zucker, JL Fleiss. Some statistical methods useful in circulation research. Circ Res 1980;47:1-9
19. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 2004;286:H742-H748
20. Yu WJ, Juang SW, Chin WT, et al. Insulin restores neuronal nitric oxide synthase expression in streptozotocin-induced diabetic rats. Life Sci 2000;68:625-634
21. Chinellato A, Froldi G, Caparrotta L, et al. Pharmacological characterization of endothelial cell nitric oxide synthase inhibitors in isolated rabbit aorta. Life Sci 1998;62:479-490
22. Literati-Nagy B, Kulcsar E, Literati-Nagy Z, et al. Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: A proof of concept randomized double-blind clinical trial. Horm Metab Res 2009;41:374-380
23. Vigh L, Literati PN, Horvath I, et al. Bimoclomol: A nontoxic, hydroxylamine derivative with stress proteininducing activity and cytoprotective effects. Nat Med 1997;3:1150-1154
24. Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-405
25. MacCarty MF. Induction of heat shock proteins may combat insulin resistance. Med Hypotheses 2006;66:527-534
26. Kolonics A, Laszlo L, Abrahamcs S, et al. BGP-15, a hydroximic acid derivative induces HSP72, activates neuronal NOS and preserves mitochondria number in hyperglycemic rat brain endothelial cell models. Fundam Clin Pharmacol 2004;18(Suppl 1):p. 67
27. Kolonics A, Literati-Nagy P, Peitl B, et al. BGP-15, a new type of insulin sensitizer. Diabetes 2006;55(Suppl 1):2091
28. Patti ME, Butte A, Cusi K, et al. Analysis of differential gene expression in skeletal muscle from subjects with insulin resistance and type 2 diabetes. Diabetes 2001;50(Suppl 2): A247
29. Kurucz I, Morva A, Vaag A, et al. Decreased expression of heat shock protein 72 in skeletal muscle of patients with type 2 diabetes correlates with insulin resistance. Diabetes 2002;51:1102-1109
30. Soti C, Nagy E, Giricz Z, et al. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005;146:769
31. Bruce CR, Carey AL, Hawley JA, et al. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes. Diabetes 2003;52: 2338-2345
32. Park HS, Lee JS, Huh SH, et al. Hsp72 functions as a natural inhibitory protein of c-Jun N-Terminal kinase. EMBO J 2001;20:446-456
33. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420: 333-336
34. Kolonics A, Horvath T, Kiss E, et al. Mitochondrial status of lymphocytes shows correlation with metabolic state. Diabetes 2006;55(Suppl 1):A143-A144
35. Hargitai J, Lewis H, Boros I, et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 2003;307: 689-695
36. Hooper PL, Hooper PL. Inflammation, heat shock proteins, and type 2 diabetes. Cell Stress Chaperones 2009;14:113-115
37. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-Analysis. Br Med J 2007;10:299
38. Ou H-Y, Cheng J-T, Yu E-H, et al. Metformin on insulin sensitivity and plasma b-endorphin in human subjects. Horm Metab Res 2006;38:106-111
39. Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-Analysis of randomized clinical trials. Diabetes ObesMetab 2008;10:1221-1238
40. Neumann A,Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study. Diabetologia 2012;55:1953-1962
41. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-156